Wang et al. showed escin could potentiate the efficacy of gemcitabine against human pancreatic cancer in vitro and in vivo via inactivation of NF-κB and consequent inhibition of c-Myc, Bcl-2, Bcl-xL, survivin, COX-2, cyclin D1, and the activation of caspase-3 [26]. This evidence concerns the gene BCL2L1 and pancreatic neoplasm.